• 1
    United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 2
    Riddle MC, Rosenstock J. Oral monotherapy and combination therapy. In: CefaluWT, GerichJE, LeRoithD eds. The CADRE Handbook of Diabetes Management. New York: Medical Information Press, 2004; 127144.
  • 3
    American Diabetes Association. American Diabetes Association (ADA) guidelines: clinical practice recommendations. Diabetes Care 2006; 29 (Suppl. 1): S1S85.
  • 4
    Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 19631972.
  • 5
    Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 15351540.
  • 6
    Shah BR, Hux JE, Laupacis A, Zinman B, Van WC. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600606.
  • 7
    Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 20782084.
  • 8
    Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 48884894.
  • 9
    Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692698.
  • 10
    Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423428.
  • 11
    Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 28742880.
  • 12
    Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368377.
  • 13
    Roden M, Laakso M, Johns D et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med 2005; 22: 11011106.
  • 14
    Burkey BF, Li X, Bolognese L et al. Combination treatment of a DPP-IV inhibitor NVP-LA237 with pioglitazone completely normalized glucose tolerance in adult obese zucker rats. Diabetes 2002; 51 (Suppl. 2): A338A339.
  • 15
    Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 20492057.
  • 16
    Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 319.
  • 17
    Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 15351547.
  • 18
    Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 15291533.
  • 19
    Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Foley JE. LAF237 is a DPP-4 inhibitor that improves model-assessed β-cell function in drug-naive patients with type 2 diabetes. Diabetologia 2004; 47 (Suppl. 1): A284A285.
  • 20
    D’Alessio DA, Watson CE, He YL et al. Restoration of an acute insulin response to glucose (AIRg) in drug-naïve patients with type diabetes (T2DM) by 3-month treatment with vildagliptin. Diabetes 2006; 55 (Suppl. 1): A108.
  • 21
    Radikova Z, Azuma K, Thomas E et al. Metabolic effects of incretin hormones I. Diabetologia 2006; 49: 401.
  • 22
    Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year. Diabetes Care 2005; 28: 19361940.
  • 23
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 11061118.
  • 24
    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004; 28: 783789.
  • 25
    Matsui J, Terauchi Y, Kubota N et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 2004; 53: 28442854.
  • 26
    Del Prato S, Marchetti P. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. Diabetes Technol Ther 2004; 6: 719731.
  • 27
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335342.
  • 28
    Writing Team for the Diabetes Control Trial. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 21592167.